Averin Capital Acquisition Corp.

What they do

Averin Capital Acquisition Corp. is a Cayman Islands-incorporated special purpose acquisition company (SPAC) formed on October 17, 2025. It has no operating business and is focused solely on identifying and completing a business combination with a target at the intersection of technology and health. It raises capital through its IPO and private placements, holds proceeds in a trust account, and seeks acquisition targets. As of June 30, 2026, it had total assets of $287.9 million, including cash and equivalents of $339,276.

Revenue drivers

• Public Units — 25,000,000 units sold at $10.00 each in the February 2026 IPO, generating gross proceeds of $250,000,000.
• Option Units — 3,386,008 units sold at $10.00 each on March 5, 2026, under partial exercise of the over-allotment option, generating additional gross proceeds of $33,860,080.
• Private Placement Units — 200,000 units sold to the Sponsor at $10.00 each, generating $2,000,000 in gross proceeds.

Recent performance

For the three months ended June 30, 2026, the company reported no revenues, consistent with its status as a blank check company. Total assets as of June 30, 2026 were $287.9 million, while total liabilities were $15.8 million, resulting in shareholder equity of -$15.2 million. Cash and equivalents stood at $339,276. The company had $283,860,080 in its trust account from the IPO, private placement, and option exercise proceeds. As of the latest report, it had not yet identified or announced a business combination target.

Strategy

The company is focusing its search for a business at the intersection of technology and health. It intends to use the proceeds held in trust to fund a business combination. Management expects to incur significant costs in pursuing acquisition plans. There is no assurance that a business combination will be successful, and the company has until February 20, 2028 (or May 20, 2028 with a definitive agreement) to complete a deal.

Risks

• Business combination failure — The company may not identify and complete a business combination by February 20, 2028, which would trigger dissolution and redemption of public shares.
• Negative shareholder equity — As of June 30, 2026, shareholder equity was -$15.2 million, indicating liabilities exceed assets, which could raise going-concern concerns.
• Limited operating history — The company was formed in 2025 and has no operations or revenue, making it entirely dependent on the success of its target search.
• Trust account investment restrictions — Trust funds can only be invested in specified U.S. government securities, money market funds, or bank deposits, limiting potential returns.

Outlook

Management states that the company must consummate a business combination by February 20, 2028, or within an extension if a definitive agreement is in place by that date. It will continue evaluating potential technology and health targets. If no deal is completed, the company will wind up and redeem public shares from the trust account. Forward-looking statements indicate actual results could differ materially from expectations.